Novo News: Boardroom Rift Expected to Refocus Drugmaker on U.S. Growth Strategy
We’ve reached a turning point at Novo. The Danish drugmaker known for its blockbuster weight-loss treatment has seen a boardroom shake-up: its chair and several independent directors are stepping down.This is more than just a governance drama. It’s a signal of a strategic reset. Novo’s biggest shareholder has pushed for change and now wants the…